v3.25.2
Income Taxes - Summary of Total Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax asset:    
net operating loss carryforward $ 26,334 $ 23,957
Intellectual property sale 3,405 3,405
Capitalized R&D 4,185 2,915
Other 994 438
Total deferred tax asset 34,918 30,715
Valuation Allowance (34,779) (30,590)
Total net deferred tax assets 139 125
Deferred tax liability:    
Operating lease right-of-use assets (139) (58)
Other 0 (67)
Total deferred tax liability (139) (125)
Total net deferred taxes 0 0
IKENA ONCOLOGY INC    
Deferred tax asset:    
net operating loss carryforward 40,218 29,529
State net operating loss carryforward 13,145 8,581
R&D credit carryforwards 16,339 14,589
Capitalized start-up costs 176 196
Accruals and reserves 492 802
Stock based compensation 2,444 2,381
Lease liability 2,078 2,934
Capitalized R&E 38,007 44,366
Total deferred tax asset 112,899 103,378
Valuation Allowance (111,755) (101,221)
Deferred tax liability:    
Fixed assets (140) (603)
Right of use asset (1,004) (1,554)
Total deferred tax liability (1,144) (2,157)
Net deferred tax asset and liability before valuation allowance 111,755 101,221
Net deferred tax asset $ 0 $ 0